The initial findings of an anticipated study into the effectiveness of the Pfizer-BioNTech Covid vaccine on children ages of 5-11 were released today, and the first results seem promising. In the s…
In the second of three phases, the pharmaceutical giants enlisted 2,268 participants ages 5-11 in the United States, Finland, Poland and Spain. While those ages 12 and up have been given 30 µg doses, patients in the new study received a 10 µg dose level in a two-dose regimen.
The trial demonstrated strong immune response in the group of children one month after the second dose. That compares well – or was “non-inferior,” the companies said — to the results seen from participants ages 16-25, who were used as the control group for the analysis and were administered a two-dose regimen of 30 µg. The vaccine also was well tolerated in the younger group, with side effects generally comparable to those observed in participants ages 16-2, the companies said.
The news comes as millions of children around the country and the world return to schools for the fall semester. “Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our Covid-19 vaccine,” said Albert Bourla, Pfizer’s chairman and CEO. “We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children. Since July, pediatric cases of Covid-19 have risen by about 240 percent in the U.S.
Said Dr. Ugur Sahin, CEO and co-founder of BioNTech: “We are pleased to be able to submit data to regulatory authorities for this group of school-aged children before the start of the winter season. The safety profile and immunogenicity data in children aged 5 to 11 years vaccinated at a lower dose are consistent with those we have observed with our vaccine in other older populations at a higher dose.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer says COVID-19 vaccine safe, effective for kids ages 5 to 11Pfizer and BioNTech released data saying its vaccine is safe and effective for kids 5-11.
Read more »
Pfizer says COVID-19 vaccine works in kids ages 5 to 11Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon -- a key step toward beginning vaccinations for youngsters. The vaccine made by Pfizer and its German partner BioNTech already is available for anyone 12 and older.
Read more »
Pfizer and BioNTech say COVID-19 vaccine safe and effective in children aged 5 to 11Pfizer Inc. undefined and German partner BioNTech SE undefined on Monday announced positive results in a Phase 2/3 trial of their COVID-19 vaccine in...
Read more »
Pfizer Says COVID-19 Vaccine Works In Kids Ages 5 To 11The drugmaker said it will seek emergency use authorization for this age group in the U.S. by the end of the month.
Read more »
Pfizer says COVID-19 vaccine works in kids ages 5 to 11, will seek authorizationPfizer said its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon.
Read more »